Literature DB >> 710804

Antitumor activity of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride in a variety of experimental tumors.

F Shimizu, M Arakawa.   

Abstract

A water-soluble nitrosourea, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride (ACNU, NSC-245382), was tested for its antitumor activity against some kinds of transplantable mouse tumors. The compound was markedly active against myeloid leukemia C1498, plasmacytoma X5563, Ehrlich ascites carcinoma, and mammary tumor FM3A43, and moderately active against mammary tumor MM102 and meningeal sarcoma MS147. It appears that ACNU has a broad antitumor spectrum.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 710804

Source DB:  PubMed          Journal:  Gan        ISSN： 0016-450X


  6 in total

1.  Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872.

Authors:  A S Planting; A Ardizzoni; J Estapé; G Giaccone; G Scagliotti; T A Splinter; A Kirkpatrick; O Dalesio; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties.

Authors:  K Schieweck; J Stanek; P M Kanter; K H Schmidt-Ruppin; M Müller; A Matter
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Experimental and clinical effect of ACNU in Japan with emphasis on small-cell carcinoma of the lung.

Authors:  N Saijo; H Niitani
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Phase II trial of nimustine (ACNU; 3-[4-amino-2-methyl-5-pyrimidinyl) methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride) in patients with small cell carcinoma of the lung after failure on combination chemotherapy.

Authors:  R A Joss; P Siegenthaler; C Ludwig; P Alberto; M M Castiglione; F Cavalli
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

5.  Importance of antitumor immunity for complete cure of highly drug-sensitive leukemia in mice.

Authors:  Y Takeda; M Sekiguchi; A Matsuzawa
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

6.  Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group.

Authors:  A S Planting; T A Splinter; A Ardizzoni; J Estapé; G Giaccone; A Kirkpatrick; O Dalesio; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.